Search Results

CSL announced the 2022 Half Year Financial Results for the period ending 31st December 2021, on Wednesday, 16th February 2021 (AEDT)

We announced our 2021 Half Year Financial Results on Thursday, 18th February 2021 (AEDT).

Tax positions adopted must be and financial results.

CSL develops innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions.

We announced our 2021 Full Year Financial Results for the period ending 30th June 2021 on Wednesday, 18th August 2021 (AEST).

Rights are allocated in two tranches and vesting occurs following the disclosure of half year and full year financial results following the grant of Rights.

The financial results for each half year ended 31 December are generally reported in February each year.

In addition to delivering solid improve the efficiency of our business and the way in which financial results, we made significant contributions in the we help patients.

20th October 2020 Forward looking statements The information in this presentation is current as of the date of this presentation, and includes forward looking statements about CSL Limited and its related bodies corporate's (CSL) financial results and estimates, business prospects and product candidates in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL.

You should read these Risk Factors along with our Annual Report for the fiscal year ending 30 June 2018 and the announcement of the Financial Results to 30 June 2018, available as described under "General Information— Documents Available for Inspection", which provide a more complete description of our business and any public announcements.